Overview

A Study of JNJ-70033093 in Healthy Participants

Status:
Completed
Trial end date:
2020-11-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of a single dose of JNJ-70033093 spray dried dispersion (SDD) tablets compared with JNJ-70033093 SDD granule capsules in healthy participants under fasting conditions in Part 1 and 2 and to assess the effect of food on the bioavailability of a single dose of JNJ-70033093 SDD tablets in Part 1.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Collaborator:
Bristol-Myers Squibb